Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Navamedic ASA (NAVA.OL)
Oslo, NO
Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.84% | -2.49% | -6.86% | -19.41% | -15.95% | -23.26% | -19.77% | -51.78% | -17.52% | +126.14% | +15.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+6.4% ★ Q1'26: +4.5% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-1,442.5% Q1'26: +98.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-0.7% Q1'26: -2.2% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+2.9% Q1'26: +1.3% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+3.4% Q1'26: +1.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+35.7% Q1'26: +33.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×4.78× Q1'26: 4.09× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
386.5K
est: 4.06M (-90.5%)
|
31.84M
est: 31.20M (+2.0%)
|
46.11M
est: 63.12M (-27.0%)
|
52.59M
est: 59.07M (-11.0%)
|
55.09M
est: 56.54M (-2.6%)
|
71.30M
est: 52.72M (+35.2%)
|
88.68M
est: 49.89M (+77.7%)
|
248.35M
est: 137.00M (+81.3%)
|
209.88M
est: 137.00M (+53.2%)
|
278.44M
est: 273.00M (+2.0%)
|
382.14M
est: 376.65M (+1.5%)
|
512.00M
est: 543.49M (-5.8%)
|
531.44M
est: 527.49M (+0.7%)
|
565.36M
est: 572.00M (-1.2%)
|
595.00M
595.00M – 595.00M
+4.0% YoY
|
661.00M
661.00M – 661.00M
+11.1% YoY
|
720.00M
720.00M – 720.00M
+8.9% YoY
|
| EBITDA |
-9.67M
est: 254.3K (-3,903.5%)
|
4.13M
est: -69.61M (+105.9%)
|
9.86M
est: 242.8K (+3,960.3%)
|
-2.51M
est: -3.16M (+20.7%)
|
-8.76M
est: 10.14M (-186.4%)
|
-2.96M
est: -8.14M (+63.7%)
|
1.72M
est: 3.14M (-45.2%)
|
8.83M
est: 8.58M (+2.9%)
|
-10.23M
est: 8.58M (-219.2%)
|
16.68M
est: 17.10M (-2.4%)
|
54.27M
est: 23.59M (+130.0%)
|
37.10M
est: 48.50M (-23.5%)
|
46.55M
est: 47.07M (-1.1%)
|
47.61M
est: 51.04M (-6.7%)
|
53.09M
53.09M – 53.09M
+4.0% YoY
|
58.98M
58.98M – 58.98M
+11.1% YoY
|
64.25M
64.25M – 64.25M
+8.9% YoY
|
| EBIT |
-10.51M
est: 163.7K (-6,517.6%)
|
-2.28M
est: -85.29M (+97.3%)
|
-1.30M
est: -9.91M (+86.9%)
|
-9.60M
est: -2.06M (-366.5%)
|
-14.84M
est: -10.91M (-36.0%)
|
-9.68M
est: -14.24M (+32.0%)
|
-4.51M
est: 2.02M (-323.1%)
|
-9.91M
est: 5.53M (-279.3%)
|
-13.89M
est: 5.53M (-351.4%)
|
11.46M
est: 11.01M (+4.0%)
|
44.45M
est: 15.19M (+192.6%)
|
25.17M
est: 32.24M (-21.9%)
|
31.80M
est: 31.29M (+1.6%)
|
16.25M
est: 33.93M (-52.1%)
|
35.29M
35.29M – 35.29M
+4.0% YoY
|
39.21M
39.21M – 39.21M
+11.1% YoY
|
42.71M
42.71M – 42.71M
+8.9% YoY
|
| Net Income |
-7.57M
est: -12.24M (+38.1%)
|
-3.21M
est: -58.40M (+94.5%)
|
-8.08M
est: -6.47M (-24.7%)
|
12.82M
est: -7.58M (+269.1%)
|
-11.19M
est: 12.25M (-191.3%)
|
-7.16M
est: -10.56M (+32.2%)
|
-3.25M
est: -5.98M (+45.5%)
|
-10.93M
|
-16.46M
|
618.0K
est: 1.39M (-55.5%)
|
29.43M
est: 18.59M (+58.3%)
|
3.30M
est: 34.04M (-90.3%)
|
1.29M
est: 19.69M (-93.4%)
|
-23.54M
est: -15.11M (-55.8%)
|
1.44M
1.44M – 1.44M
+109.5% YoY
|
16.07M
16.07M – 16.07M
+1,016.7% YoY
|
32.86M
32.86M – 32.86M
+104.5% YoY
|
| SGA |
—
est: 502.4K (-100.0%)
|
—
est: 3.86M (-100.0%)
|
—
est: 15.18M (-100.0%)
|
—
est: 4.87M (-100.0%)
|
—
est: 10.05M (-100.0%)
|
—
est: 11.32M (-100.0%)
|
5.62M
est: 6.20M (-9.4%)
|
8.00M
est: 16.95M (-52.8%)
|
28.60M
est: 16.95M (+68.7%)
|
36.31M
est: 33.78M (+7.5%)
|
48.46M
est: 46.60M (+4.0%)
|
57.88M
est: 85.64M (-32.4%)
|
59.59M
est: 83.12M (-28.3%)
|
172.71M
est: 90.13M (+91.6%)
|
93.76M
93.76M – 93.76M
+4.0% YoY
|
104.16M
104.16M – 104.16M
+11.1% YoY
|
113.46M
113.46M – 113.46M
+8.9% YoY
|
| EPS |
-1.33
est: -0.69 (-92.0%)
|
-0.51
est: 0.03 (-1,768.3%)
|
-1.07
est: 0.42 (-353.1%)
|
1.70
est: -0.31 (+647.0%)
|
-1.48
est: -0.67 (-120.1%)
|
-0.95
est: -0.47 (-101.7%)
|
-0.40
est: -0.34 (-18.8%)
|
-1.24
|
-1.14
|
0.04
est: 0.08 (-51.8%)
|
1.75
est: 1.05 (+66.3%)
|
0.19
est: 1.42 (-86.6%)
|
0.07
est: 0.82 (-91.1%)
|
-0.98
est: -0.63 (-55.6%)
|
0.06
0.06 – 0.06
+109.5% YoY
|
0.67
0.67 – 0.67
+1,016.7% YoY
|
1.37
1.37 – 1.37
+104.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kathrine E. Gamborg Andreassen | Chief Executive Officer | 5M | female |
| Nils Ole Krekling | Chief Financial Officer | 4M | male |
| Astrid J. Torgersen Bratvedt | Chief Scientific Officer | — | female |
| Nina Masvaer | Commercial Director of Nordics & Head of Rx | — | — |
| Ole Henrik Eriksen | Chief Business Development Officer | — | male |
| Alexander Lidmejer | Chief Operating Officer | — | male |
| Pal Zimmermann Vonen | Director of Group Accounting | — | — |
| Annika Palo | Director of QA, Compliance & Sustainability | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NAVA.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
